Celgene
Global biopharmaceutical company committed to improving the lives of patients worldwide.
Summit New Jersey (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | - | - | 11.8b | 13.9b |
| % growth | - | - | - | 18 % |
| EBITDA | - | - | 5.4b | 5.6b |
| % EBITDA margin | - | - | 46 % | 40 % |
| Profit | - | - | 2.7b | 3.7b |
| % profit margin | - | - | 23 % | 26 % |
| R&D budget | 3.4b | 4.2b | 3.3b | 4.0b |
| R&D % of revenue | - | - | 28 % | 29 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
| N/A | N/A | IPO | |
* | $74.0b | Acquisition | |
| Total Funding | - | ||
Related Content
Recent News about Celgene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by Eli Lilly May 2018
exited
ACQUISITION by Adaptive Biotechnologies Jan 2015
ACQUISITION by Celgene Jan 2018
exited
exited
exited
ACQUISITION by Ipsen Jun 2022
ACQUISITION by Celgene Dec 2009